The superfamily of G protein-coupled receptors (GPCRs) contributes in diverse physiological and pathological functions and represents a major target for current therapeutic drugs and agents under development. Nevertheless, the endogenous ligands of more than 140 GPCRs remain unidentified, 1 consequently these receptors are called orphan receptors or orphan GPCRs. An orphan GPCR has a similar structure to others GPCRs but whose endogenous agonist has not yet been identified. On the other hand, if an endogenous agonist for an orphan receptor is discovered, the receptor becomes "adopted".
GPR35 is an orphan GPCR first identified in 1998 by O'Dowd et al. 2 after a screen of a human genomic library. This receptor is predominantly expressed in immune and gastrointestinal tissue, with notable expression in the ileum, the spleen, and the pancreas. This receptor has garnered much interest as a potential therapeutic target through its association with a range of diseases, including stomach cancer, 3 ulcerative colitis, 4 and heart failure. 5 Given the association of GPR35 with various inflammatory conditions, including cardiovascular diseases, Divorty et al. 6 in this issue of American Journal of Hypertension (Vol, issue, 2018) made the intriguing hypothesis that GPR35 contributes of angiotensin (Ang) II-induced hypertension, despite the previously reported findings that GPR35 knockout (KO) mice have a significant increase in basal systolic blood pressure compared with the wild-type (WT) controls. 5 In contrast to these data, Divorty et al. observed no differences in mean arterial pressure between GPR35 KO and WT prior to Ang II infusion. After Ang II treatment, however, GPR35 KO mice were protected from significant increases in mean arterial pressure, systolic blood pressure, and diastolic blood pressure. Furthermore, GPR35 KO mice, unlike the WT controls, were able to maintain their ejection fraction in the face of Ang II-infusion, which supports some of the other previous reports suggesting GPR35 is associated with myocardial abnormalities and dysfunction. 5, 7 What was not clarified from the current investigation by Divorty et al. was whether the lowered blood pressure in GPR35 mice was from a direct inability of Ang II to activate GPR35 on important cardiovascular organs (e.g., endothelial cells, vascular smooth muscle cells, myocardium, or kidneys), or whether GPR35 KO mice were indirectly protected from Ang II-induced hypertension, possibly by a reduction in potential molecules that can activate GPR35. These observations have important implications for the understanding of the mechanisms associated with the development and/or maintenance of this devastating disease.
Given the lack of potent and selective ligands, as well as the consensus endogenous ligand for GPR35, elucidating its function has been difficult. Nonetheless, three potential endogenous molecules have been identified, including kynurenic acid, chemokine CXCL17, and 5-hydroxyindoleacetic acid. Kynurenic acid is a byproduct of the normal metabolism of amino acid L-tryptophan. Kynurenic acid is known to be elevated in the blood of different pathological conditions (e.g., type 2 diabetes, multiple sclerosis, inflammatory bowel disease, and chronic kidney disease). 8 The mechanism by which kynurenic acid becomes elevated in the blood is subject to much research, but it has been suggested to be a result of systemic low-grade inflammation. 9 One of the major rate-limiting enzymes for kynurenic acid biosynthesis is indolamine 2,3-dioxygenase. Proinflammatory cytokines can induce the expression of indolamine 2,3-dioxygenase, and subsequently the generation of kynurenic acid. 8 Interestingly, given that the proinflammatory properties of Ang II are without question, 10 it is possible to infer that Ang II-dependent cytokines production could stimulate indolamine 2,3-dioxygenase to generate kynurenic acid that would subsequently act on GPR35.
CXCL17 is an orphan chemokine that is primarily expressed in gastric mucosa, where it undergoes endoproteolysis during protein maturation. 11 Mature CXCL17 exhibits strong chemoattractant abilities for monocytes and macrophages via mitogen-activated protein kinases ERK1/2 and p38. 11 CXCL17 also induces the production of proinflammatory factors vascular endothelial growth factor and cyclooxygenase 2. 11 While the specific role of CXCL17 in Ang II-induced hypertension is currently unknown, it is conceivable that, similar to kynurenic acid, the proinflammatory properties of Ang II could stimulate the production of CXCL17, which could then lead to GPR35 activation.
One other possible metabolite that could explain why GPR35 KO mice are protected from Ang II-induced hypertension is the less reported ligand of GPR35, 5-hydroxyindoleacetic acid. 12 Similar to kynurenic acid, 5-hydroxyindoleacetic acid is another L-tryptophan metabolite, but it is also the main metabolite of serotonin, a potent vasoconstrictor, 13 and a metabolite known to increase after Ang II infusion. 14 Therefore, it is also plausible that 5-hydroxyindoleacetic acid also contributes to Ang IIdependent hypertension and therefore explain why GPR35 KO mice are protected from high blood pressure.
Another question that perhaps would be relevant for the pathophysiology of hypertension and urgently needs to be addressed is whether Ang II could be a novel ligand for GPR35. This is because GPR35 is expressed on tissues that have an important role on the regulation of blood pressure, such as vascular smooth muscle cells and endothelial cells, 15 and GPR35 KO mice are protected from Ang II-induced hypertension. 6 Therefore, it is plausible that direct Ang II-GPR35 interaction could contribute to deleterious vascular remodeling that promotes the development and maintenance of hypertension (Figure 1) .
The identification of various orphan receptors offers novel therapeutic avenues for the treatment of disease. Nonetheless, understanding their pathophysiological significance is difficult to interpret. In other words, what is a receptor without a known ligand/stimulus to activate it? Emerging from the field of hypertension are a number of novel mediators of high blood pressure and vascular dysfunction. Frequently, these are cited as neoantigens or damage-associated molecular patterns, 16 and it is possible that they could be novel ligands for orphan receptors, such as GRP35. While Divorty et al. 6 clearly observed a contribution of this receptor in the context of Ang II-dependent hypertension, the mechanism of receptor activation remains to be confirmed. Nonetheless, based on the currently available scientific literature, it is certainly conceivable that kynurenic acid, CXCL17, and/or 5-hydroxyindoleacetic acid could be elevated in response to Ang II infusion to act on GPR35 or Ang II directly could "adopt" this orphan receptor. Figure 1 . In angiotensin (Ang) II-induced hypertension, GPR35 could potentially be activated by kynurenic acid, chemokine CXCL17, or 5-hydroxyindoleacetic acid, or plausibly by a direct activation by Ang II itself. Activation of GPR35 in vascular cells would promote the pathogenesis of hypertension by causing endothelial cell proliferation and vascular smooth muscle cell migration. 15 Downloaded from https://academic.oup.com/ajh/article-abstract/31/9/973/5032628 by guest on 23 January 2020
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